Bright Minds Biosciences Inc.
DRUG
CNSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 49.49% | 9.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 101.36% | 411.56% | |||
| Operating Income | -101.36% | -411.56% | |||
| Income Before Tax | 106.44% | -449.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 106.44% | -449.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 106.44% | -449.71% | |||
| EBIT | -101.36% | -411.56% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 104.64% | -448.86% | |||
| Normalized Basic EPS | 104.69% | -448.64% | |||
| EPS Diluted | 104.58% | -453.41% | |||
| Normalized Diluted EPS | 104.30% | -463.51% | |||
| Average Basic Shares Outstanding | 37.79% | 0.25% | |||
| Average Diluted Shares Outstanding | 48.42% | -3.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
